Does the media refer more to BMY or RPRX?

In the previous week, Bristol Myers Squibb had 55 more articles in the media than Royalty Pharma. MarketBeat recorded 64 mentions for Bristol Myers Squibb and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.87 beat Bristol Myers Squibb's score of 0.65 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 27 Very Positive mention(s) 9 Positive mention(s) 16 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SNY or RPRX?

Sanofi has higher revenue and earnings than Royalty Pharma. Sanofi is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 1.92 $8.84B $1.91 20.48 Royalty Pharma $2.38B 13.68 $770.95M $1.45 39.01

Is SNY or RPRX more profitable?

Royalty Pharma has a net margin of 32.14% compared to Sanofi's net margin of 8.66%. Royalty Pharma's return on equity of 30.01% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Royalty Pharma 32.14% 30.01% 14.91%

Does the media favor SNY or RPRX?

In the previous week, Royalty Pharma had 3 more articles in the media than Sanofi. MarketBeat recorded 9 mentions for Royalty Pharma and 6 mentions for Sanofi. Royalty Pharma's average media sentiment score of 0.87 beat Sanofi's score of 0.56 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GSK or RPRX?

GSK has higher revenue and earnings than Royalty Pharma. GSK is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.17 $7.54B $3.20 14.45 Royalty Pharma $2.38B 13.68 $770.95M $1.45 39.01

Is GSK or RPRX more profitable?

Royalty Pharma has a net margin of 32.14% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Royalty Pharma's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Royalty Pharma 32.14% 30.01% 14.91%

Does the media favor GSK or RPRX?

In the previous week, GSK had 12 more articles in the media than Royalty Pharma. MarketBeat recorded 21 mentions for GSK and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.87 beat GSK's score of 0.51 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 5 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAK or RPRX?

Royalty Pharma has a consensus target price of $61.57, indicating a potential upside of 8.84%. Given Royalty Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Royalty Pharma is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Royalty Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media refer more to TAK or RPRX?

In the previous week, Royalty Pharma had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for Royalty Pharma and 1 mentions for Takeda Pharmaceutical. Royalty Pharma's average media sentiment score of 0.87 beat Takeda Pharmaceutical's score of 0.32 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RPRX or TEVA?

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Royalty Pharma. MarketBeat recorded 22 mentions for Teva Pharmaceutical Industries and 9 mentions for Royalty Pharma. Teva Pharmaceutical Industries' average media sentiment score of 0.91 beat Royalty Pharma's score of 0.87 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 11 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Royalty Pharma (RPRX) Competitors

$58.54 +1.97 (+3.48%)

As of 12:46 PM Eastern

Compare

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

Should you buy Royalty Pharma stock or one of its competitors? Royalty Pharma's main competitors and comparable companies include Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Royalty Pharma compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Bristol Myers Squibb presently has a consensus price target of $64.88, suggesting a potential upside of 14.37%. Royalty Pharma has a consensus price target of $61.57, suggesting a potential upside of 8.84%. Given Bristol Myers Squibb's higher probable upside, analysts clearly believe Bristol Myers Squibb is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	16 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.47
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Bristol Myers Squibb had 55 more articles in the media than Royalty Pharma. MarketBeat recorded 64 mentions for Bristol Myers Squibb and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.87 beat Bristol Myers Squibb's score of 0.65 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	27 Very Positive mention(s)	9 Positive mention(s)	16 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has a net margin of 32.14% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Royalty Pharma	32.14%	30.01%	14.91%

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.4%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.7%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has raised its dividend for 17 consecutive years and Royalty Pharma has raised its dividend for 5 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has higher revenue and earnings than Royalty Pharma. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.40	$7.05B	$4.54	12.50
Royalty Pharma	$2.38B	13.68	$770.95M	$1.45	39.01

Bristol Myers Squibb has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Bristol Myers Squibb beats Royalty Pharma on 12 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to Sanofi?

Sanofi (NASDAQ:SNY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Royalty Pharma had 3 more articles in the media than Sanofi. MarketBeat recorded 9 mentions for Royalty Pharma and 6 mentions for Sanofi. Royalty Pharma's average media sentiment score of 0.87 beat Sanofi's score of 0.56 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanofi currently has a consensus price target of $49.50, suggesting a potential upside of 26.53%. Royalty Pharma has a consensus price target of $61.57, suggesting a potential upside of 8.84%. Given Sanofi's higher probable upside, research analysts plainly believe Sanofi is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Sanofi has higher revenue and earnings than Royalty Pharma. Sanofi is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	1.92	$8.84B	$1.91	20.48
Royalty Pharma	$2.38B	13.68	$770.95M	$1.45	39.01

Royalty Pharma has a net margin of 32.14% compared to Sanofi's net margin of 8.66%. Royalty Pharma's return on equity of 30.01% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Royalty Pharma	32.14%	30.01%	14.91%

Sanofi has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.5%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.7%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 5 consecutive years.

Summary

Royalty Pharma beats Sanofi on 14 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to GSK?

GSK (NYSE:GSK) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

GSK has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Royalty Pharma	32.14%	30.01%	14.91%

15.7% of GSK shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, GSK had 12 more articles in the media than Royalty Pharma. MarketBeat recorded 21 mentions for GSK and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.87 beat GSK's score of 0.51 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	5 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has higher revenue and earnings than Royalty Pharma. GSK is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.17	$7.54B	$3.20	14.45
Royalty Pharma	$2.38B	13.68	$770.95M	$1.45	39.01

GSK currently has a consensus price target of $55.33, suggesting a potential upside of 19.67%. Royalty Pharma has a consensus price target of $61.57, suggesting a potential upside of 8.84%. Given GSK's higher probable upside, equities analysts plainly believe GSK is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.05
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.8%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.7%. GSK pays out 55.3% of its earnings in the form of a dividend. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Royalty Pharma beats GSK on 11 of the 19 factors compared between the two stocks.

How does Royalty Pharma compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Royalty Pharma has lower revenue, but higher earnings than Takeda Pharmaceutical. Royalty Pharma is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.10	-$1.01B	$0.34	54.57
Royalty Pharma	$2.38B	13.68	$770.95M	$1.45	39.01

Royalty Pharma has a consensus target price of $61.57, indicating a potential upside of 8.84%. Given Royalty Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Royalty Pharma is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 32.14% compared to Takeda Pharmaceutical's net margin of 3.80%. Royalty Pharma's return on equity of 30.01% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Royalty Pharma	32.14%	30.01%	14.91%

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Royalty Pharma had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for Royalty Pharma and 1 mentions for Takeda Pharmaceutical. Royalty Pharma's average media sentiment score of 0.87 beat Takeda Pharmaceutical's score of 0.32 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.7%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 5 consecutive years.

Summary

Royalty Pharma beats Takeda Pharmaceutical on 17 of the 19 factors compared between the two stocks.

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Royalty Pharma (NASDAQ:RPRX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Teva Pharmaceutical Industries has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.68	$770.95M	$1.45	39.01
Teva Pharmaceutical Industries	$17.26B	2.78	$1.41B	$0.60	68.69

Royalty Pharma has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Royalty Pharma. MarketBeat recorded 22 mentions for Teva Pharmaceutical Industries and 9 mentions for Royalty Pharma. Teva Pharmaceutical Industries' average media sentiment score of 0.91 beat Royalty Pharma's score of 0.87 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	11 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma presently has a consensus target price of $61.57, suggesting a potential upside of 8.84%. Teva Pharmaceutical Industries has a consensus target price of $45.50, suggesting a potential upside of 10.39%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Royalty Pharma and Teva Pharmaceutical Industries tied by winning 8 of the 16 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPRX vs. The Competition

Export

Metric	Royalty Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$33.67B	$12.43B	$7.28B	$13.01B
Dividend Yield	1.63%	2.63%	2.51%	22.89%
P/E Ratio	40.38	807.81	275.44	25.42
Price / Sales	14.15	748.21	559.80	78.81
Price / Cash	12.10	86.65	77.16	53.04
Price / Book	3.48	9.19	10.66	5.96
Net Income	$770.95M	$2.84B	$3.50B	$380.62M
7 Day Performance	3.14%	-3.85%	-3.65%	-3.75%
1 Month Performance	-0.86%	-7.95%	-8.06%	-6.62%
1 Year Performance	62.61%	-5.71%	2.58%	-4.38%

Royalty Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPRX Royalty Pharma	3.8231 of 5 stars	$58.54 +3.5%	$61.57 +5.2%	+59.6%	$33.67B	$2.38B	40.38	100
BMY Bristol Myers Squibb	4.6689 of 5 stars	$57.64 -2.5%	$65.08 +12.9%	+30.3%	$120.77B	$49.19B	12.69	32,500	Trending News Analyst Forecast
SNY Sanofi	4.3506 of 5 stars	$39.74 -0.8%	$49.50 +24.6%	-19.8%	$97.15B	$49.35B	20.81	74,846
GSK GSK	3.7738 of 5 stars	$46.81 +0.7%	$55.33 +18.2%	+5.9%	$94.06B	$43.07B	14.64	66,841	Trending News Dividend Cut High Trading Volume
TAK Takeda Pharmaceutical	2.0266 of 5 stars	$18.68 -0.3%	N/A	+35.3%	$60.02B	$28.32B	54.93	47,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPRX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

How does Royalty Pharma compare to Bristol Myers Squibb?

Summary

How does Royalty Pharma compare to Sanofi?

Summary

How does Royalty Pharma compare to GSK?

Summary

How does Royalty Pharma compare to Takeda Pharmaceutical?

Summary

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

How does Royalty Pharma compare to Bristol Myers Squibb?

Do analysts recommend BMY or RPRX?

Does the media refer more to BMY or RPRX?

Is BMY or RPRX more profitable?

Is BMY or RPRX a better dividend stock?

Which has preferable earnings & valuation, BMY or RPRX?

Which has more risk & volatility, BMY or RPRX?

Do insiders & institutionals have more ownership in BMY or RPRX?

Summary

How does Royalty Pharma compare to Sanofi?

Does the media favor SNY or RPRX?

Do analysts prefer SNY or RPRX?

Which has higher earnings and valuation, SNY or RPRX?

Is SNY or RPRX more profitable?

Which has more volatility & risk, SNY or RPRX?

Do institutionals and insiders believe in SNY or RPRX?

Is SNY or RPRX a better dividend stock?

Summary

How does Royalty Pharma compare to GSK?

Which has more volatility & risk, GSK or RPRX?

Is GSK or RPRX more profitable?

Do insiders and institutionals have more ownership in GSK or RPRX?

Does the media favor GSK or RPRX?

Which has preferable valuation & earnings, GSK or RPRX?

Do analysts prefer GSK or RPRX?

Is GSK or RPRX a better dividend stock?

Summary

How does Royalty Pharma compare to Takeda Pharmaceutical?

Which has preferable valuation and earnings, TAK or RPRX?

Do analysts prefer TAK or RPRX?

Is TAK or RPRX more profitable?

Do insiders and institutionals have more ownership in TAK or RPRX?

Does the media refer more to TAK or RPRX?

Which has more volatility and risk, TAK or RPRX?

Is TAK or RPRX a better dividend stock?

Summary

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Which has higher valuation & earnings, RPRX or TEVA?

Which has more volatility & risk, RPRX or TEVA?

Is RPRX or TEVA more profitable?

Does the media favor RPRX or TEVA?

Do analysts prefer RPRX or TEVA?

Do insiders and institutionals have more ownership in RPRX or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools